Forecast Ledgerinterventional psychiatry and psychedelic medicineQuoted, dated predictions scored against public outcomes under one written method. Every score links to the words, the rule and the evidence.

Not admitted · Not a forecast

Rules 1.1.0 · as of 14 Sep 2026

Quote

Not a forecast

“Helena is the right partner to help position Lykos in its transition from a research-focused public benefit company, wholly owned by a nonprofit, to a PBC with mission-aligned investors focused on obtaining FDA approval and insurance coverage for prescription use of MDMA-assisted therapy by appropriate patients with PTSD.”
· MAPS Welcomes New Investors, Name Change for MAPS Public Benefit Corporation · article

MAPS post announcing the $100M Series A led by Helena and the renaming of MAPS PBC to Lykos Therapeutics. Doblin frames Lykos' goal as obtaining FDA approval and insurance coverage.

Descriptive, retrospective, or a statement of preference; no future state asserted.